Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults
- Conditions
- Prehypertension
- Interventions
- Dietary Supplement: Nitric Oxide supplementDietary Supplement: Placebo
- Registration Number
- NCT01937754
- Lead Sponsor
- Neogenis Laboratories
- Brief Summary
Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy adults with clinical prehypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
- Adults between the ages of 18 to 80 years
- Two blood pressure readings of >/=135/80 mmHg at rest, thus representing prehypertension
- Informed consent
- Existence of any significant internal or cardiovascular disease;
- Current use of any antihypertensive medication.
- Inability to give informed consent, or fill out standard questionnaires or inability to follow up clinically.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nitric Oxide supplement Nitric Oxide supplement - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Reduction in Systolic and Diastolic Blood Pressure Readings 30 days Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.
- Secondary Outcome Measures
Name Time Method Improvement in Functional Capacity 30 days Participant will take a six minute walk test at baseline and again after thirty days during the follow-up appointment. Achieved distances will be measured and recorded.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
California Medical Institute
🇺🇸Beverly Hills, California, United States